Estimated equipotent conversion ratios of morphine, sufentanil and fentanyl as continuous infusion in neonatal intensive care units: a pharmacoepidemiologic cohort study.

IF 2.4 3区 医学 Q3 PHARMACOLOGY & PHARMACY European Journal of Clinical Pharmacology Pub Date : 2025-03-01 Epub Date: 2024-12-27 DOI:10.1007/s00228-024-03796-1
Manon Tauzin, Inès Cavalier, Matthieu Ortala, Camille Jung, Béatrice Gouyon, Xavier Durrmeyer
{"title":"Estimated equipotent conversion ratios of morphine, sufentanil and fentanyl as continuous infusion in neonatal intensive care units: a pharmacoepidemiologic cohort study.","authors":"Manon Tauzin, Inès Cavalier, Matthieu Ortala, Camille Jung, Béatrice Gouyon, Xavier Durrmeyer","doi":"10.1007/s00228-024-03796-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Opioids are frequently used to treat pain in neonatal intensive care units (NICU) with fentanyl, morphine and sufentanil being mainly used agents. Equianalgesic potency between opioids is not clearly described in the neonatal population. The aim of this study was to compare theoretical and actual equipotent conversion ratios between morphine, sufentanil and fentanyl based on prescriptions.</p><p><strong>Methods: </strong>In this observational, multicentric, pharmacoepidemiologic study, prescriptions' data (doses, duration of use, patients' characteristics) were collected and analyzed for all neonates hospitalized in one of the 30 Level III French NICUs using the same prescription software (Logipren®) and who received at least one prescription of morphine, sufentanil or fentanyl as continuous infusion during a 6-year period (2014-2020).</p><p><strong>Results: </strong>Among 65,555 neonates, 8361 (12.8%) received a prescription of continuous opioid infusion in one of the 30 French NICUs: 5054 (60.4%) received sufentanil, 2413 (28.9%) morphine and 894 (10.7%) fentanyl. After conversion to equipotent morphine doses using theoretical conversions ratios of 50:1 for morphine/fentanyl ratio and 500:1 for morphine/sufentanil ratio, prescribed mean maintenance doses of fentanyl and sufentanil were two times and five times higher than morphine doses, respectively. In this cohort, potency conversion ratios between the different opioids were 20:1 for morphine/fentanyl ratio and 100:1 for morphine/sufentanil ratio, and 4:1 for fentanyl/sufentanil ratio (theoretical conversion ratio of 7: 1).</p><p><strong>Conclusion: </strong>In a large cohort of neonates treated with continuous opioids in NICU, fentanyl and sufentanil doses used were significantly higher than morphine doses when using theoretical conversion ratios.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"375-381"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00228-024-03796-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Opioids are frequently used to treat pain in neonatal intensive care units (NICU) with fentanyl, morphine and sufentanil being mainly used agents. Equianalgesic potency between opioids is not clearly described in the neonatal population. The aim of this study was to compare theoretical and actual equipotent conversion ratios between morphine, sufentanil and fentanyl based on prescriptions.

Methods: In this observational, multicentric, pharmacoepidemiologic study, prescriptions' data (doses, duration of use, patients' characteristics) were collected and analyzed for all neonates hospitalized in one of the 30 Level III French NICUs using the same prescription software (Logipren®) and who received at least one prescription of morphine, sufentanil or fentanyl as continuous infusion during a 6-year period (2014-2020).

Results: Among 65,555 neonates, 8361 (12.8%) received a prescription of continuous opioid infusion in one of the 30 French NICUs: 5054 (60.4%) received sufentanil, 2413 (28.9%) morphine and 894 (10.7%) fentanyl. After conversion to equipotent morphine doses using theoretical conversions ratios of 50:1 for morphine/fentanyl ratio and 500:1 for morphine/sufentanil ratio, prescribed mean maintenance doses of fentanyl and sufentanil were two times and five times higher than morphine doses, respectively. In this cohort, potency conversion ratios between the different opioids were 20:1 for morphine/fentanyl ratio and 100:1 for morphine/sufentanil ratio, and 4:1 for fentanyl/sufentanil ratio (theoretical conversion ratio of 7: 1).

Conclusion: In a large cohort of neonates treated with continuous opioids in NICU, fentanyl and sufentanil doses used were significantly higher than morphine doses when using theoretical conversion ratios.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新生儿重症监护病房持续输注吗啡、舒芬太尼和芬太尼的等效转化率:一项药物流行病学队列研究。
目的:阿片类药物是新生儿重症监护病房(NICU)治疗疼痛的常用药物,以芬太尼、吗啡和舒芬太尼为主。阿片类药物之间的等镇痛效力在新生儿群体中尚未明确描述。本研究的目的是比较吗啡、舒芬太尼和芬太尼在处方上的理论和实际等效转化率。方法:在这项观察性、多中心的药物流行病学研究中,收集并分析了使用相同处方软件(Logipren®)在法国30个III级nicu之一住院的所有新生儿的处方数据(剂量、使用时间、患者特征),这些新生儿在6年期间(2014-2020年)接受了至少一次吗啡、舒芬太尼或芬太尼连续输注处方。结果:65,555名新生儿中,有8361名(12.8%)在法国30家新生儿重症监护病房之一接受了阿片类药物持续输注处方;5054名(60.4%)接受了舒芬太尼,2413名(28.9%)接受了吗啡,894名(10.7%)接受了芬太尼。按照吗啡/芬太尼比值50:1和吗啡/舒芬太尼比值500:1的理论换算比例转换为等效吗啡剂量后,芬太尼和舒芬太尼的处方平均维持剂量分别比吗啡剂量高2倍和5倍。在本队列中,吗啡/芬太尼的效价转换比为20:1,吗啡/舒芬太尼的效价转换比为100:1,芬太尼/舒芬太尼的效价转换比为4:1(理论转换比为7:1)。结论:在NICU连续使用阿片类药物的大型新生儿队列中,使用理论转换比时,芬太尼和舒芬太尼的剂量明显高于吗啡剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.40
自引率
3.40%
发文量
170
审稿时长
3-8 weeks
期刊介绍: The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.
期刊最新文献
Drug-drug interaction of phenytoin sodium and methylprednisolone on voriconazole: a population pharmacokinetic model in children with thalassemia undergoing allogeneic hematopoietic stem cell transplantation. Estimated equipotent conversion ratios of morphine, sufentanil and fentanyl as continuous infusion in neonatal intensive care units: a pharmacoepidemiologic cohort study. Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma. Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis. Drug safety during pregnancy: a challenging and ever moving field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1